1435. The Cost-Effectiveness of Vaccinating With an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina

Objective: Influenza is an infection of the respiratory system with a high annual incident rate. Influenza vaccinecan reduce the severity of influenza and prevent transmission of the virus. Influenza vaccines in Thailand are theTrivalent Influenza Vaccine (TIV) and the Quadrivalent Influenza Vaccine (QIV). The cost and the effectiveness ofthe QIV in preventing transmission of the virus are greater than the TIV. Until now, no studies have been conductedto compare the economic impact of using QIV or TIV. This study aimed to evaluate the economic effects of usingQIV versus TIV in Thai populations age 60 years and over.Materials and Methods: The study was carried out from a societal perspective for cost per DALYs averted. A decisiontree model was used to analyse the costs and DALYs averted of Thais after they received the vaccine.Results: In a period of one year, it was found that in Thais age 60 years and over, the total cost of TIV was 2,445.19baht with 0.0094 DALYs and total cost of the QIV was 2,629.28 baht with 0.0082 DALYs and the incremental costeffectivenessratio (ICER) of the QIV was 158,489.24 baht per DALYs averted. The acceptability curves demonstratedthat the probability of QIV being cost-effective was 95% of the willingness to pay, being 1.2 times the Thai grossnational income per capita.Conclusion: Therefore, in Thai people age over 60 years and over, QIV is more cost-effective than TIV. The resultsof this study can be used by policymakers to help inform their decisions about which influenza vaccine is morecost-effective.

Download Full-text

A Systematic Review Of The Cost-Effectiveness Of Quadrivalent Influenza Vaccine

Value in Health ◽

10.1016/j.jval.2016.09.393 ◽

2016 ◽

Vol 19 (7) ◽

pp. A414

Author(s):

BM van Maanen ◽

MJ Postma ◽

PT de Boer

Keyword(s):

Systematic Review ◽

Cost Effectiveness ◽

Influenza Vaccine ◽

The Cost ◽

Quadrivalent Influenza Vaccine

Download Full-text

Cost-effectiveness of influenza vaccination of adult cancer patients

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.6079 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 6079-6079

Author(s):

E. B. Avritscher ◽

C. D. Cooksley ◽

J. M. Geraci ◽

B. N. Bekele ◽

S. B. Cantor ◽

...

Keyword(s):

Cost Effectiveness ◽

Influenza Vaccine ◽

Cancer Patients ◽

Vaccination Strategy ◽

Vaccine Effectiveness ◽

Third Party ◽

Decision Analytic Model ◽

Accounting System ◽

Increased Risk ◽

The Cost

6079 Background: Despite recommendations to immunize all patients at increased risk from underlying immunosuppressive disease against influenza, many insurance plans do not cover the vaccine. We analyzed the cost-effectiveness of vaccinating adult cancer patients against influenza from the perspective of a third-party payer. Methods: We developed a decision-analytic model using epidemiological, vaccine effectiveness, resource utilization, cost, and utility data from published sources, supplemented with data collected from our institutional accounting system. Two strategies were compared: vaccination of adult cancer patients against influenza, and no vaccination. The cost-effectiveness analysis included charges (inflated to 2005 US$) for vaccination, influenza-related hospitalizations, physician and emergency visits, and the average wholesale price for prescription drugs and influenza vaccine. The base-case patient for the model was assumed to be a 67-year-old cancer patient (the median age at initial cancer diagnosis - all sites - for the 1998–2002 SEER population) with active disease. Results: The effectiveness of the no vaccination strategy was 4.665 QALYs at a cost of $95.23. The effectiveness of the influenza vaccine was 4.672 QALYs at a cost of $70.73. Thus, the vaccination strategy provided an incremental effectiveness of 0.007 QALYs over the no vaccination strategy at a reduction in cost of $24.50. Based on these gains, we estimate that vaccination of all adult cancer patients could potentially save third-party payers over $87 million in addition to gains in clinical benefits. The model was not sensitive to plausible changes in cancer survival, incidence of influenza, vaccine effectiveness, vaccine price, and risk of influenza-related hospitalization. Conclusions: Influenza vaccine is cost-effective for adult cancer patients. Health plans should expand their coverage to include the vaccine for adult patients with cancer. No significant financial relationships to disclose.

Download Full-text